# A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Clinical trial · Eli Lilly and Company

- Archive id: nct:NCT07794579
- Published: 2026-08-31
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07794579
- Source URL: https://clinicaltrials.gov/study/NCT07794579
- Provenance: clinicaltrials

## Abstract

This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: ATTAIN-NOW
- status: RECRUITING
- phase: PHASE3
- study type: INTERVENTIONAL
- enrollment: 2001
- sponsor: Eli Lilly and Company
- conditions: Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal
- interventions: DRUG: Orforglipron; DRUG: Placebo
- start date: 2026-08-26
- start date type: ACTUAL
- primary completion date: 2029-08-01
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

Cited in dossiers:
- [GLP-1 & Incretin Therapies: State of the Field (October 2026)](https://space-kitty.com/dossiers/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.